Comparative Pharmacology
Head-to-head clinical analysis: ULO versus WAYRILZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ULO versus WAYRILZ.
ULO vs WAYRILZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ULO is a brand name for the drug ublituximab, a monoclonal antibody that targets CD20 on B-cells, leading to B-cell lysis via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.
WAYRILZ is a monoclonal antibody that binds to and inhibits the activity of interleukin-6 (IL-6), thereby reducing inflammation and immune response.
100 mg orally twice daily for 7 days
WAYRILZ 500 mg orally twice daily without regard to meals.
None Documented
None Documented
Terminal elimination half-life is 1.5-3 hours (mean 2.2 hours) in adults with normal renal function; prolonged to 20-30 hours in severe renal impairment (CrCl <15 mL/min), necessitating dose adjustment.
Clinical Note
moderateUlobetasol + Gatifloxacin
"The risk or severity of adverse effects can be increased when Ulobetasol is combined with Gatifloxacin."
Clinical Note
moderateUlobetasol + Rosoxacin
"The risk or severity of adverse effects can be increased when Ulobetasol is combined with Rosoxacin."
Clinical Note
moderateUlobetasol + Levofloxacin
"The risk or severity of adverse effects can be increased when Ulobetasol is combined with Levofloxacin."
Clinical Note
moderateUlobetasol + Trovafloxacin
Terminal elimination half-life is 12 hours, supporting twice-daily dosing in patients with normal renal function.
Primarily renal (60-80% as unchanged drug) via glomerular filtration and active tubular secretion; remainder as inactive metabolites. Biliary/fecal excretion accounts for <10%.
Renal elimination of unchanged drug accounts for 85% of total clearance; fecal/biliary elimination accounts for 12%, with the remainder via metabolic inactivation.
Category C
Category C
Unknown
Unknown
"The risk or severity of adverse effects can be increased when Ulobetasol is combined with Trovafloxacin."